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DENDRITIC CELL REGULATION OF PERIPHERAL
TOLERANCE IN POLYCLONAL T CELL REPERTOIRES
Revati F. Masilamani, Ph.D.
The Rockefeller University 2008
Dendritic cells (DCs) play a pivotal role in determining whether the outcome
of the immune system's encounter with antigen will be immunity or
tolerance. Using an antibody against the DEC-205 receptor, antigens have
been delivered specifically to DCs in vivo. Under steady state conditions,
such presentation of antigen leads to peripheral tolerance in transgenic T
cells, either by deletion, anergy or the induction of regulatory T cells. We
wanted to examine whether delivery of autoantigens to DCs using this
approach, could be used to tolerize autoreactive polyclonal T cells, thereby
preventing autoimmunity in mouse models. We succeeded in inducing
tolerance to the myelin oligodendrocyte protein and preventing disease in
the experimental autoimmune encephalomyelitis model. However no halt or
delay in onset of autoimmune diabetes was observed when insulin was
targeted to DCs in the non-obese diabetic (NOD) mouse model. Also,
foreign antigen-specific T cell responses could not be abolished by targeting
antigen to DCs in the NOD mouse. These results strongly suggested that
establishing peripheral tolerance in disease-prone polyclonal repertoires such

as in the NOD model, would be far more challenging than the previously
studied tolerance in non-autoreactive transgenic models had been. We
recognized that success in DC-targeting-based autoimmune therapy would
first require a better understanding of tolerance in non-disease prone
polyclonal T cell repertoires. Towards that end, we examined T cell
tolerance in C57BL/6 mice. In the steady state, targeting ovalbumin (OVA)
to DCs resulted in polyclonal CD4 and CD8 T cell tolerance. This tolerance
was non-deletional and characterized by persistence of T cells that produced
IFNγ, but no IL-2. CD4 dependent antibody production by B cells in vivo
was abrogated. Also, both CD4 and CD8 proliferative responses in vitro
were abolished. Subsequent to tolerization, depending on the strength of the
costimulatory stimulus that the

CD4 and CD8 T cells are exposed to,

tolerance can be reversed both in vivo and in vitro. Thus our results
demonstrate that while tolerance in non-autoreactive polyclonal repertoires
in steady state DC environments can be achieved, reversal of the tolerized
state can also occur. This suggests that in autoreactive T cell repertoires in
chronically inflamed DC environments, the prevention or treatment of
autoimmune disease is a challenge that will require comprehensive
understanding of the balance between immunity and tolerance.
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Chapter 1
Introduction

Central Tolerance
The immune system has evolved to recognize foreign antigen from self
antigen so that it can respond to invaders and protect the host, while
remaining tolerant to self. The continual ability to make this distinction is
fundamentally important in avoiding self-destructive immune responses and
was recognized as such by Ehrlich and Morgenroth at the turn of the last
century (1). They referred to this as horror autotoxicus. Owen and Hasek (2,
3) demonstrated that encounter with foreign tissue during embryonic
development leads to life-long tolerance against the antigens expressed in
the tissue. These results were extended by Billingham and Medawar, when
they demonstrated acquired tolerance to foreign blood cells and skin grafts
in animals that had been exposed during neonatal development to tissues
from the donor(4). These results were interpreted to mean that the
developing immune system was malleable and if a foreign subtsance was
introduced early enough, it would induce tolerance rather than immunity.
Burnet, in 1957, synthesized these experimental findings into the theory of
clonal selection, which postulated that lymphocytes with receptor

1

specificities against antigens present during embryonic development, would
be selectively eliminated by a process of deletion. To this day Burnet’s
theory forms the fundamental framework for understanding how
immunological tolerance is induced.

The clonal selection theory has been directly validated by studies that
observed the deletion of T cells in the thymus, bearing T cell receptors that
recognize

endogenous

antigens

in

the

context

of

the

Major

Histocompatibility (MHC) Class I and II molecules (5-7). Immature
autoreactive thymocytes enounter their cognate antigen during development
and get deleted by apoptotic cell death (8) that ensures the absence of these
clones from the mature repertoire that enters the periphery from the thymus.
This process, referred to as negative selection, was thought to be mediated
by bone marrow- derived antigen presenting cells (APCs) (9, 10), likely
thymic dendritic cells (DCs). Subsequently thymic medullary DCs were
shown to mediate thymic deletion both in vitro (11) and in vivo (12).

Central tolerance to self-antigens has to account for two categories of
antigens: those that are ubiquitously expressed and those that have tissue
specific distribution (13). It has been reported that many tissue specific
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antigens are expressed promiscuously (14, 15)

in medullary thymic

epithelial cells (mTECs) under the regulation of AIRE (autoimmune
regulator), a gene identified from patients with a rare autosomal recessive
disorder known as autoimmune polyglandular syndrome type 1 (APS-1).
Affected patients develop spontaneous autoimmune disease targeted
pimarily at endocrine organs (16). In mice deficient in AIRE expression in
mTECs, the expression of a subset of tissue specific antigens is abrogated,
resulting in the failure of negative selection in the thymus (17-20).Studies
suggest that in addition to AIRE there are other, as yet unknown factors that
direct expression of tissue specific antigens in mTECs and are thus involved
in central tolerance (18). It has been shown that mTECs can directly mediate
negative selection of CD8 T cells against tissue specific antigens by
presentation on their MHC Class I molecules. Thymic DCs on the other
hand can acquire tissue specific antigens from mTECs either by uptake of
apoptotic cells, or nibbling of surface membranes of live cells, then process
for MHC class I and class II presentation, and delete both CD8 and CD4 T
cells (21).

Negative selection in the thymus, while presenting a sophisticated and
coherent model for self tolerance, cannot explain every instance of tolerance
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encountered through the life of the animal. For instance, some self antigens
are only expressed in the body after the stage of early T cell development in
the thymus (22), and most innocuous environmental antigens that are
tolerated are also unavailable for antigen presentation during negative
selection. Additionally, it has been shown that some low-affinity
autoreactive T cells escape thymic negative selection because the strength of
signal transduction upon TCR engagment by the cognate antigen-MHC
complex is below the threshold required for induction of apoptosis (23).The
fact that despite these limitations of thymic negative selection, and the
documented presence of autoreactive T cells in the periphery (24, 25) most
individuals do not succumb to autoimmunity, suggested the existence of
extrathymic mechanisms to enforce tolerance.

Peripheral Tolerance
It was observed that mature T cells could be tolerized to non-self antigens
that were either injected (26, 27) or expressed as endogenous antigens (28)
independent of thymic selection. This form of extrathymic tolerance was
called peripheral tolerance and both CD4 and CD8 T cells were shown to be
potential targets of this form of tolerance (27, 29, 30). Peripheral tolerance
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of T cells was shown to abrogate both T-helper dependent antibody
production (31) as well as autoimmune disease (29, 32).

The initial challenge to the study of peripheral tolerance was how to exclude
the involvement of thymic mechanisms in the analysis of tolerance
induction. An early solution to the problem, was the use of antibodies that
blocked the presentation of antigens on endogenous MHC molecules during
thymic development (33). Another approach involved the transfer of H-Y
specific TCR transgenic T cells into male recipients that express the H-Y
antigen. Transferred T cells intially proliferated in response to the H-Y
antigen in the periphery, but were later subjected to extrathymic deletion and
anergy (28). Similar results were obtained in models that studied T cell
response to novel, extrathymic antigens, transgenically expressed under
tissue specific promoters (34-36). While T cell production and survival in
the thymus was unchanged in these experiments, autoreactive clones in the
periphery were deleted, thus making a strong case for a mode of tolerance
that was solely regulated in the periphery.

That there is an intricate regulation of peripheral tolerance, was underscored
by studies where the transgenic expression of novel proteins in the periphery
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did not result in tolerance (37, 38) and sometimes even led to autoimmunity
(39). It was observed that newly made peripheral proteins were ignored by
antigen- specific T cells, but could cause autoimmunity if their expression
was concurrent with viral infection or ectopic expression of IL-2 (40-42). A
significant observation was that the expression levels of novel proteins could
influence the fate of antigen specific T cells. If a protein was expressed at
high levels, it favored the deletion of T cells (43-46). All these findings
point to an extremely delicate balance between the regulation of tolerance
and immunity that depends on multiple checkpoints. Antigen presenting
cells as the initiators of the cascade that leads to an immune response are
therefore at the apex of this regulation.

Dendritic Cells in Immunity and Tolerance
As antigen presenting cells, dendritic cells (DCs) have been revealed in the
last two decades to be critical to the balance between tolerance and
immunity. Soon after their discovery (47-49), dendritic cells, so called
because of their long astral processes, were shown to be potent stimulators
of T cells. They were able to initiate primary immune responses (50-53),
induce polarization in T cells, to generate Th1 and Th2 responses (54), and
most recently Th17 responses (55) and were used successfully for
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therapeutic immune reponses in human patients (56). DCs efficiently
process peptides from soluble antigens (57) and also present them on both
class I and class II complexes in vitro (57, 58) and ex vivo (59). DCs also
uptake dying cells and process and present their antigens to T cells (60, 61).
Recently in work described below DCs have been targeted in vivo with Class
I and Class II antigens, for processing and presentation to CD4 and CD8 T
cells (62-64).

DCs are found throughout the body so they come into contact with antigens
in tissues all over. They are present in skin (65), the airways (66), blood
(67), lymphatics (68), lymphoid organs (48) and interstitial parenchymal
spaces (69). Dendritic cells are an ephemeral population with a life-span of a
few days (49, 70), however they are highly mobile and migrate upon antigen
enounter to lymphoid organs (71). Also it was recently shown that DCs
divide in situ in peripheral tissues, and peptide-MHC complexes are
transferred to the daughter DCs (72).

DCs use several types of receptors for antigen uptake such as Fc receptors of
Type I, II (73) and III (74), complement receptors (75), scavenger receptors
(76) and C-type lectin receptors (77, 78). In recent years, the C-type lectin
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receptors have been targeted by genetically engineered antibodies carrying
antigens for specific delivery to DCs. The first lectin receptor to be targeted
was the DEC-205 receptor, which has an unusual trafficking pathway that
passes through late endosomes leading to effective antigen presentation (79).
Subsequently the DC-SIGN receptor (80), DCIR2 (63), and Langerin (81),
of the lectin family of receptors, have been targeted for antigen delivery to
the DCs.

The initiation of immunity by DCs is regulated by the presence of
costimulatory, activating molecules and receptors on their surface as well as
the induction of cytokines. Some of the important costimulatory molecules
are Ig family members such as CD80 and CD86 (82), B7-DC (83), PD-L1
(84), PD-L2 (85) and TNF family member CD30 (86). These molecules
form ligand-receptor pairs with their counterparts on T cells such as CD28
(87), CTLA-4 (88) and PD-1 (84). DCs express several classes of receptors
such as Toll-like receptors (TLRs), Tumor Necrosis Factor family receptors
(TNF-Rs) and cytokine receptors. The TLRs are involved in the recognition
of signals associated with infection and tissue damage, and are therefore
seen as a link between innate and adaptive immunity. The binding of their
pathogenic ligands such as lipopolysaccharide (89, 90) peptidoglycans, CpG
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(91) and others, lead to a cascade of downstream signaling resulting in the
activation of transcription factors such as NF- κB involved in survival,
differentiation and inflammation responses (92). In addition to their role in
antigen uptake, Fc receptors can also trigger both activatory and inhibitory
signaling cascades (93-95). CD40 is an important TNF family receptor that
is involved in

feedback activation of DCs by CD4 helper cells that

upregulate CD40L after intial activation (96, 97). Upon activation DCs
upregulate the production of pro-immune cytokines such as IL-12 (75) and
IFNα (98). The concerted involvement of all these DC activation pathways,
leads to the activation of T cells and consequent immunity.

The role for DCs in tolerance was demonstrated by the targeting of antigens
to the DEC-205 receptor in the absence of adjuvant (64). An antibody
against the DEC-receptor expressed mainly on CD8 DCs, was cloned and
fused to a peptide from hen egg lysozyme (HEL) (αDEC/HEL). When DCs
were targeted in vivo with this construct in the absence of adjuvant, they
presented antigen to HEL-specific T cells and the consequence of this steady
state presentation was the deletion of the T cells and ultimately tolerance
against future challenge with HEL. In contrast if the αDEC/HEL was
delivered along with an inflammatory stimulus, the consequence of antigen
9

presentation to T cells was persistent activation and immunity. The model
that emerged from this paradigmatic study was that the context in which
DCs in vivo present antigen to T cells, governs the fate of the T cells. Under
normal steady state conditions, defined as the absence of inflammation or
infection, the presentation of antigen by DCs leads to T cell tolerance. In
contrast, under conditions of inflammation and tissue injury, the DCs
acquire an activated phentotype and the presentation of antigen to T cells in
this context leads to immunity against the antigen (99).

Recently the DCIR2 molecule on the CD8- subset of DCs was targeted for
antigen delivery by a monoclonal antibody and the consequence of such
targeting was tolerance. Using transgenic T cells against OVA, the
presentation efficiencies of the DEC-205 and DCIR2 receptors was
compared. It was demonstrated that the DCIR2 targeting strategy leads to
superior Class II presentation, while the DEC-205 targeting strategy leads to
better Class I presentation of antigen to T cells (63).

Mechanisms of Peripheral Tolerance
DCs can induce tolerance in T cells by several different mechanisms. T cell
ignorance defined as the lack of antigen recognition was observed in several
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cases of endogenously expressed novel antigens (40, 41) and was postulated
to be responsible for some forms of tolerance. However as a mechanism it is
a very limited explanation for the life-long tolerance against a wide-range of
self and harmless non-self antigens that an animal constantly encounters.

Deletion is a characteristic mechanism of peripheral tolerance observed
among responding T cells (28, 33, 35, 45, 46). A characteristic feature of
such deletion is an initial clonal expansion, preceeding the disappearance of
autoreactive T cells. Peripheral deletion has some resemblance to activation
induced cell death, an important pathway to terminate immune responses.
There have been examples of Fas induced death of T cells in tolerance (100)
and TNF involvement (101), but other mechanisms of deletion may exist
that are yet to be discovered.

Anergy as a form of tolerance involves a state of unresponsiveness of T
cells, that otherwise remain viable and persist for long periods of time in an
organism (102). Initially anergy that resulted from incomplete signaling to
the T cells was reported. In such cases anergy was maintained by a block in
the Ras/MAP kinase pathway, could be reversed by IL-2 or anti-OX40
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signaling, and usually did not result in the inhibition of effector functions
(82, 103, 104).

Other forms of anergy have now been shown that require complete initial
activation of the T cells by stimulatory CD28 and inhibitory CTLA-4
signaling (105). We have shown that upon antigen targeting to steady state
DCs, transgenic T cells against the myelin oligodendrocyte protein were
rendered anergic. This anergy required initial activation of T cells and was
characterized by the upregulation of CD5. Upon blocking with αCD5
antibody, we could restore antigen-specific responsiveness of the T cells in
vivo. Thus CD5 in this model, acts as an inhibitor of T cell signaling (106).
CD5 is a glycoprotein that acts as both a positive and negative regulator of
T cell activation (107-111). The intracellular domain of CD5 contains
sequences resembling both an immunoreceptor tyrosine-based activatory
motif (ITAM) and an inhibitory motif (ITIM), that may explain the dual
nature of CD5 function(112).

One of the pathways of anergic tolerance involves an early block in tyrosine
kinase activation, which predominantly inhibits calcium mobilization, and
an independent mechanism that blocks signaling through the IL-2 receptor
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(102). The reduction in IL-2 levels has been shown to be an important
element in antigen-specific anergy, and results in an anti-proliferative state
of the T cells (113-115). Thus anergy has several pathways, and is an
important mechanism for tolerance in the periphery.

Regulatory T cells (T regs) have become an intensely studied subset of T
cells in recent years. It was observed that early thymectomy of mice causes
general autoimmune disease (116). This observation was explained by an
apparent decrease of CD4+CD25+ cells in thymectomized animals, which
was later confirmed by successful prevention of autoimmunity by transfer of
syngenic CD4+CD25+ cells (116). In vitro, CD4+CD25+ cells were shown
to suppress proliferation of other cells by IL-2 production in a cell contactdependent manner that also required TCR activation of the CD4+CD25+
cells. Recently it has been shown that antigen-loaded mature DCs can
induce expansion of CD4+CD25+ T cells in vitro, and that these cells can
actively suppress CD4+CD25- proliferation in response to splenic APCs
(117). This approach was then used to expand CD4+CD25+ transgenic T
cells from a non-obese diabetic strain to prevent and treat autoimmune
diabetes (118, 119). CD4+CD25+ suppressors specifically express the
transcription factor Foxp3, which regulates their development and
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function(120). Mutations in Foxp3 lead to widespread autoimmunity (120122). It was shown that antigen targeting to the DCs in minute doses in
steady state in vivo, led to the conversion of CD4+CD25- effector cells into
CD4+ CD25+ Foxp3+ T cells (123). These cells require IL-2 for their
maintenance and activation and the lack of IL-2 results in reduced numbers
of these cells in vivo (124-126). In contrast to the requirement of cell contact
for in vitro suppression, there are many reports that indicate that cytokines
such as IL-10 and TGF-β are needed in vivo for mediating suppression or
conditioning a suppressive milieu (127, 128). Another subset of T regs is
made under tolerogenic conditions and produces IL-10 which has been
shown to have suppressive function in vivo in conditions of inflammation
(129). T regs are therefore an important component of the regulation of T
cell tolerance in vivo.

Thus the establishment and maintenance of tolerance in the periphery is
intricately regulated by the interdependence of DCs and T cells and their
relationships with other cells of the immune system.
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Dendritic Cells and Polyclonal T cell Tolerance:
Questions and an Outline of Experimental Systems
To study peripheral tolerance DCs were targeted by antigen using an αDEC205 antibody, and transgenic T cell models were used to study the outcome
of such presentation of antigen. It was observed that under steady state,
presentation of antigens to the T cells led to T cell tolerance and depending
on the model studied, tolerance was achieved by deletion (62, 64), anergy
(106), or the induction of regulatory T cells (123). Based on these studies,
we decided to examine whether such targeting of antigen could lead to T cell
tolerance in an autoimmune disease model and whether such tolerance
would result in prevention and treatment of the disease.

Autoimmunity is the breakdown of tolerance against self, and subsequent
tissue destruction by autoreactive T cells and B cells. While genetic predisposition to autoimmunity leads to the selection of autoreactive T cells
during thymic selection, peripheral tolerance check points also break down
in individuals that are autoimmune. Thus the induction of peripheral
tolerance by a strategy such as the one described above would help to keep
in check autoreactive T cells in the periphery.
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The animal models we chose for these studies, were the experimental
autoimmune Encephalomyelitis model (EAE) (130, 131), an induced, acute
mouse model for mutiple sclerosis, and the Non-Obese-Diabetic Mouse
(NOD) (132), which is a spontaneous, chronic model for autoimmune Type
1 diabetes. The myelin oligodendrocyte peptide (MOG) (35-55) was the
autoantigen against which tolerance was examined in the EAE model. In the
NOD model, the 9-23 peptide from the β chain of insulin was used for
targeting therapy.

Our results showed that targeting of MOG antigen to the DCs in the EAE
model leads to tolerance and prevention of progression to disease. In the
NOD model, however chronic targeting of insulin could not prevent
development of disease. The difference in therapy outcomes in the two
models, highlighted the need for a better understanding of tolerance in
polyclonal repertoires since all the previous studies on the outcome of
antigen targeting to DCs had been done in transgenic T cell models. As the
first step in understanding polyclonal tolerance, we examined the C57BL/6
model, a non-disease prone repertoire, for tolerance to CD4 and CD8
antigens from Ovalbumin.
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The results described in this thesis, show that antigen targeting to DCs in
non-disease prone mice leads to polyclonal CD4 and CD8 tolerance. This
tolerance is non-deletional, as the cells persist with alterations in their
effector cytokine profiles. The tolerized CD4 T cells, lose the ability to make
IL-2, but not IFNγ. Tolerized CD4 T cells are unable to provide help to B
cells for antibody production and thus humoral tolerance is established. CD4
and CD8 cells that have been tolerized in vivo lose their ability to proliferate
in response to antigen. Stimulation with αCD28 in vitro and αCD40 in vivo
leads to a reversal of tolerance.

The reversible nature of the tolerance induced in a non-disease polyclonal
repertoire suggests that establishment and maintenance of tolerance in
disease models will be a challenge, since the immune environment in such
cases is chronically inflamed. Antigen presentation in that context by DCs,
to low affinity disease-prone polyclonal T cells could potentially lead to
immunity or reversal of tolerance. These results provide important insight
for the future development of successful DC-based therapeutic strategies for
autoimmune disease.

17

Chapter 2

Materials and Methods
Mice: All mice used in experiments were maintained under specific
pathogen free conditions. 5-8 week old B6.SJL (CD45.1), NOD/LtJ, and
C57BL/6 mice were purchased from Jackson Laboratory. B6.H2g7 were
maintained by breeding. The mice were used according to institutional
guidelines. Protocols were approved by the Institutional Animal Care and
Use Committee at The Rockefeller University.

Mice were injected subcutaneously with protein in complete freund’s
adjuvant (CFA) and intraperitoneally (i.p) with chimeric antibodies.

Immunizations: Mice were primed either once i.p. or multiple times with
5µg αDEC/peptide antibodies, or with 5μg αDEC/peptide antibody in
conjunction with 50μg αCD40 (clone IC10) (as indicated in Results) or the
same doses of αCD40 alone or with 100µg of LPS-free OVA (Seikagaku
Corp.) precipitated in alum (Pierce Chemical Co.)). Antibodies were elicited
by boosting the mice once i.p. with 1µg OVA-NP11, which is a conjugate of
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11 molecules of the hapten (4-hydroxy-3-nitrophenyl) acetyl (NP) with the
carrier protein (OVA).

EAE induction: C57BL/6 females 6-8 weeks old, were injected with 100μg
MOG peptide in CFA (Difco) (200μl total) divided into two parts and
injected into each flank. This was immediately followed by i.p injection with
200ng Pertussis Toxin (List BioLabs) in PBS. Another dose of Pertussis
Toxin (PTX) was injected 48 hours later. CFA used for injection was
enriched with mycobacterium TB (10ml CFA +40 mg M. TB from Difco).

Diabetes Experiments:

For all diabetes experiments, development of

diabetes was monitored with chemstrips (Roche Applied Science), which
detect urine glucose above 150 mg dL–1. A mouse was considered diabetic
on the first of three consecutive readings of high urine glucose. Diabetes was
monitored from the time mice were 11 weeks old, until they were 25-30
weeks old.

Adeno/GAG p41 immunization: Mice received one dose (1x107 PFU per
mouse) of recombinant adenovirus/GAG p41 intramuscularly (i.m).
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Construction and production of the hybrid antibodies: The entire cDNA
encoding chicken OVA was cloned in frame with the carboxyl terminus of
the heavy chain of mouse αDEC-205 or isotype control III/I0 antibodies.
Likewise, a 52 base pair sequence comprising amino acids 9-23 from the
insulin β chain peptide, was cloned into the antibodies to produce
αDEC/INS or III/I0/INS. Hybrid antibodies were produced by transient
transfection in 293T cells using calcium phosphate as described previously
(64), and the fusion antibodies were purified on Protein G columns (GE
Healthcare). They were assayed for binding to DEC-205 expressed stably on
the surface of CHO cells, provided by C.G. Park (The Rockefeller
University, New York, NY). Titrations ranging from 5μg/ml to 0.01μg/ml
were tested, and the binding was detected using a secondary αmouse IgG.

Peptide libraries: Peptides for OVA and GAG p41 were synthesized in
collaboration with the Proteomics Resource Center, The Rockefeller
University. For in vitro restimulation assays, the OVA peptide 75 (epitope
265-279 EKLTEWTSSNVMEER) was used, which consists of both Class I
and Class II epitopes. For GAG p41 experiments, the entire peptide library
of GAG p41 was pooled.
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Intracellular cytokine staining: Intracellular IFNγ and IL-2 production by
CD4 and CD8 T cells after immunization, was evaluated using bulk
splenocytes incubated with 2 µM of the OVA or GAG p41 peptide or
medium alone in the presence of 2 µg/ml of costimulatory •CD28 antibody
(clone 37.51). Cells were cultured for 6 h in the presence of brefeldin A (BD
Biosciences), incubated with CD16/CD32 antibody to block Fc receptors,
and stained with anti-mouse CD4 (clone GK 1.5), CD8 (clone 53-6.7), and
CD3 (clone 145-2C11) antibodies for 15 min at 4°C. After fixation with
Cytofix/Cytoperm Plus (BD Biosciences), cells were stained for intracellular
IFNγ- (XMG1.2) for 15 min at room temperature. All mAbs were purchased
from BD Biosciences. Data was collected using FACSCalibur and analyzed
using FlowJo software (Tree Star).

In vitro Proliferation Assay: We used CFSE (107 cells/ml, 1 µM, 10 min,
37°C; Invitrogen) dilution to assess proliferation of primed T cells in
response to antigen. Bulk splenocytes were labeled with CFSE, and added at
500, 000 cells per well, in the presence of OVA peptide (2 µg/ml), medium
alone, or •CD3 (0.1 µg/ml) and •CD28 (2 µg/ml; positive control) for 4 days
in 1 ml round-bottom tubes.
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ELISA: For the detection of NP- or OVA-specific antibodies, high-binding
ELISA plates (Costar) were coated overnight with 5 µg/ml NP2-BSA
(Biosearch Technologies) or OVA protein (Sigma) in PBS. Plates were then
washed three times with PBS-Tween 20 0.02% and blocked with PBS-BSA
1% for 1 h at room temperature. Serial dilutions of the sera in PBS-BSA
0.25% were incubated for 2 h at room temperature and visualized with goat
•mouse

IgG Fc-specific antibody conjugated to horseradish peroxidase

(1:2,000; Jackson ImmunoResearch Laboratories) followed by colorimetric
assay using 1-Step ABTS. OD405 was measured using a VERSAmax
microplate reader (Molecular Devices). Titers represent the highest dilution
of serum showing an OD405 >0.1. The results are presented as the log10
antibody titer of each individual mouse.

LUMINEX Assay for cytokines: 14 days after immunization, bulk
splenocytes were isolated and cultured with or without αCD28 in the
presence of peptide or medium alone for 72 hrs. The supernatants were then
harvested and assayed on the LUMINEX instrument using the Biosource
Multiplex Bead Immunoassay kit for detection of TNFα, IFNγ, IL-17,
IL-10, and IL-4.
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Statistical Analysis: All comparisons between groups used Welch’s t-test to
reject the null hypothesis that the means of the groups being compared are
identical. The Welch’s t-test is a modification of the standard Student’s t-test
which can be used to compare groups with different variances (133). The
null hypothesis was rejected if the p-value was less than 0.05. Analysis was
performed using MATLAB (Mathworks, MA). Error bars represent one
standard error of the mean.
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Chapter 3
Results Part I
Targeting of antigen to DCs in an autoimmune disease model
The ability to establish peripheral T cell tolerance in transgenic models
against antigens targeted to DCs, suggested that a similar targeting approach
could be used to deliver self-antigens to DCs for presentation to autoreactive
polyclonal T cells in mouse models of autoimmune disease. If such an
approach resulted in tolerance of autoreactive polyclonal T cells, it would be
a promising advance towards therapy of autoimmune disease.

We chose the mouse model of experimental autoimmune encephalomyelitis
(EAE), to examine the consequences of targeted self-antigen delivery to
DCs. EAE resembles the human neurodegenerative disorder- multiple
sclerosis (MS), and is mediated by the destruction of the neuronal myelin
sheath by T cells that are specific for myelin epitopes. In mice, EAE can be
induced by immunization with myelin oligodendrocyte (MOG) peptide
35-55. This immunization leads to the activation of MOG-specific CD4 T
cells, which then home into the central nervous system by infiltrating the
blood-brain barrier, ultimately leading to neuronal destruction (131). We
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decided to examine the consequences of targeted delivery of MOG peptide
to DCs, on the pathology of the disease.

Daniel Hawiger, designed hybrid DC targeting antibodies that consisted of
the MOG 35-55 peptide fused to the carboxyl terminus of the cloned αDEC
(referred to as αDEC/MOG) and isotype control (III/10 /MOG) heavy chains
(Figure 1A). Using these antibodies we demonstrated that MOG- specific
transgenic CD4 T cells, could be tolerized by targeting MOG peptide to
steady state DCs for presentation to T cells (106). We therefore wanted to
determine whether αDEC/MOG targeting to DCs would lead to the
prevention of MOG peptide-mediated disease in the EAE model. Disease
was induced by activating MOG peptide-specific T cells by injection of
MOG peptide in CFA, followed by injection of Pertussis Toxin (PTX) to
breech the blood-brain barrier.

C57BL/6 mice were injected with

αDEC/MOG or isotype control III/10/MOG or PBS and 7 days later
immunized with 100μg MOG peptide in CFA subcutaneously, followed by
two doses of PTX. The condition of the mice was monitored daily. Within
two weeks after immunization with MOG peptide in CFA followed by PTX,
controls injected with PBS or III/10/MOG had developed symptoms of EAE.
In contrast, all but one of the αDEC/MOG- treated mice remained
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completely disease-free, and the one mouse that developed symptoms
showed only very mild disease (Figure 1B). The mice were monitored for
the next 10 days and no significant change in their condition was detected.

To examine whether the prevention of disease in αDEC/MOG treated mice,
was due to some form of T cell tolerance, we assessed homing capacity of
CD4 T cells to the spinal cords in tolerized versus control mice. While
increased numbers of CD4 T cells were detected in spinal cords from control
treated mice that showed symptoms of EAE, no such cells were found in
spinal cords from mice that were treated with αDEC/MOG prior to
immunization with MOG peptide in CFA and PTX (Figure 1C). Thus
treatment with αDEC/MOG blocked the homing capacity of CD4 T cells to
the spinal cord and effectively prevented induction of EAE.

The success of the dendritic cell targeting strategy to prevent disease in EAE
which is an induced acute autoimmune model, encouraged us to attempt the
challenge of therapy in a spontaneous chronic mouse model of
autoimmunity. The model that we chose was the Non Obese Diabetic (NOD)
mouse which closely resembles human automimmune type I diabetes in its
pathology, immunology and genetics.
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Our goal was to induce antigen specific T cell tolerance by delivering
diabetogenic antigens to DCs in NOD mice, and thereby delay or prevent the
development of diabetes. We chose the 9-23 insulin β chain peptide as our
antigen for delivery to DCs since it has been reported in many studies to be
the immunologically dominant epitope in the pathology of the disease in
both mice and humans and there is a high degree of conservation of this
epitope across species (134). To deliver this antigenic insulin epitope to DCs
in vivo, we generated hybrid antibodies with the insulin peptide fused to the
carboxyl terminus of the heavy chain of either the cloned αDEC (referred to
as αDEC/INS) or the III/10 Isotype control (referred to as III/10/INS) heavy
chain. The DNA constructs encoding these hybrid antibodies were
transiently transfected into 293T cells, and the protein was purified from the
supernatant (Figure 2A).

To test whether the hybrid αDEC antibody bearing the insulin peptide was
able to bind to the DEC-205 receptor, we did an in vitro binding assay on
CHO cells that stably expressed the DEC-205 receptor on their surface. The
αDEC/INS antibody was able to bind the DEC-205 receptor even at
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concentrations as low as 0.1μg/ml, while the III/I0/INS antibody showed no
binding even at a concentration of 5μg/ml (Figure 2B).

To determine whether αDEC/INS targeting altered the onset of diabetes, we
treated groups of 10 NOD females each, beginning at age 4 weeks, with
αDEC/INS, or III/10 INS or PBS every 10 days. We injected doses ranging
from 15μg to 0.005μg of αDEC/INS and III/I0/INS in multiple independent
experiments. Mice were tested for urine glucose levels every week for upto
25- 30 weeks. While the first experiment seemed to suggest that lower doses
of αDEC/INS could retard the onset of diabetes (Figure 3A), this was not
borne out by subsequent experiments (Figure 3B and C). We did not observe
an abrogation or significant retardation in onset of diabetes. Thus delivery of
insulin peptide to DCs in NOD mice did not result in protection against
development of diabetes.

In summary, delivery of the MOG antigen to steady state DCs led to the
absence of CD4 T cell accumulation in the spinal cord and the prevention of
disease in the EAE model. In the NOD model however, delivery of insulin
antigen to the DCs failed to block the development of diabetes. There are
many possible reasons for this striking difference in outcomes between the
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two disease models. One important difference is that in the NOD model,
antigen is being delivered to DCs that are in a chronically inflamed
environment, in contrast to the EAE model where inflammation only sets in
upon induction of disease. Also in EAE which is an induced model of
disease, the T cells do not see their antigen, until immunization, while in
NOD, the insulin antigen is constantly in circulation from well before
treatment begins. These and other considerations on the difference between
the two disease models and its implications for treatment are discussed in
detail in Chapter 6.
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Figure 1. Vaccination with αDEC/MOG prevents EAE in C57BL/6 wild
type mice.
A) Schematic representation of the αDEC/MOG hybrid antibody.
B) Groups of 10 C57BL/6 mice each, were injected with either PBS or
15μg of αDEC/MOG or III/I0/MOG, as indicated. 8 days after
antibody or PBS injection the mice were challenged with 100μg
MOG peptide in CFA s.c. along with Pertussis Toxin i.p. The mice
were monitored for disease symptoms daily and scored on days 14
and 21 post-immunization. The following clinical scale was used: 0no clinical signs, 1- flaccid tail, 2-hind limb weakness and abnormal
gait, 3- complete hind limb paralysis, 4- complete limb paralysis. The
scores were the same on days 14 and 21. Results represent scores
from day 21.
C) Some of the animals from the experiment described above were
sacrificed on day 21 after disease induction and their spinal cords
were removed, processed and analysed by flow cytometry.
Histograms show intensity of staining with αCD4 APC among cells
in the lymphoid gate.
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Figure 2. Characterization of the hybrid αDEC/INS and III/I0/INS
antibodies.
A) SDS PAGE analysis of purified αDEC/INS and III/I0/INS hybrid
antibodies followed by Coomassie staining.
B) αDEC/INS and III/I0/INS antibodies were tested for in vitro binding to
DEC-205 , expressed on CHO cells (Titration range 5μg/ml - 0.01
μg/ml). Histogram plots show mean fluorescence intensity of staining
with secondary •mouse IgG.
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Figure 3. Chronic treatment with αDEC/INS did not prevent or delay
onset of diabetes.
(A, B and C) Groups of 10 NOD females each, were injected every other
week, beginning at 4 weeks of age, with the indicated doses of αDEC/INS,
III/I0/INS or PBS till they were 25 weeks old. Beginning at age 11 weeks,
the mice were tested weekly for urine glucose levels, and a positive was
scored if the mouse tested glucose high, two consecutive times in a row.
Graphs represent 3 independent experiments with different doses of
antibodies.
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Chapter 4
Results Part II
Targeting of Antigen to DCs in NOD mice
Prior to the studies described in this thesis, the consequences of antigen
targeting to DCs had only been examined using transgenic T cell models.
Our findings detailed in the previous chapter revealed the complexities of
achieving tolerance in spontaneous wild type disease models with chronic
inflammation such as NOD. We therefore decided to dissect the
consequences of DC- targeted antigen delivery to polyclonal T cell
repertoires at a cellular level in the NOD model. Since in NOD mice, the
study of tolerance to insulin is complicated by a variety of factors, both
genetic and immunological, we decided to first simply ask whether
polyclonal T cells in NOD mice could be tolerized against a harmless
foreign antigen by DC targeting.

Towards this end, we set out to identify a foreign antigen that could generate
detectable antigen specific T cell responses in a polyclonal NOD repertoire.
The NOD MHC Class II molecule I-Ag7, has an unstable peptide binding
groove due to a non-aspartic acid substitution at position 57 of the β chain
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(135), which precludes high affinity binding with many antigenic epitopes.
To find an antigen whose epitope could be presented by the I-Ag7, we
screened a panel of hybrid αDEC antibodies bearing different antigenic
proteins and peptides (HIV GAG p41, circumsporozoite protein from
Plasmodium yoelii, ovalbumin protein from chicken egg, and myelin
oligodendrocyte peptide) in B6.H2g7 mice. The B6.H2g7 congenic strain has
the NOD H2g7 locus (H2g7 = Kd, I-Ag7, I-Enull and Db) introgressed onto the
C57BL/6 background (136). As controls we used C57BL/6 mice, known to
generate either strong CD4 or CD8 T cell responses against all the antigens
screened.

We immunized the mice with 5μg of hybrid αDEC antibody in conjunction
with 50μg of αCD40 antibody, as had been reported in C57BL/6 mice for
the induction of robust T cell responses (137, 138). The αCD40 antibody
acts as an agonist for the CD40 receptor expressed on DCs. This interaction
bypasses the need for the CD40 ligand on activated CD4 T cells to bind the
receptor. αCD40 thus acts as a potent stimulator of DC maturation and
thereby immunity. Two weeks after immunization bulk splenocytes isolated
from the immunized mice were restimulated in vitro with αCD28 and
antigenic peptides. Intracellular IFNγ responses were then assayed by flow
37

cytometry. The p41 protein of HIV GAG (GAG p41) was the only antigen
amongst those tested that generated detectable IFNγ responses in CD4 T
cells in B6.H2g7 (Figure 4A), while all other antigens (Figure 4B and data
not shown) did not. We therefore chose to target GAG p41 to DCs to probe
polyclonal T cell immunity and tolerance in NOD.

NOD, B6.H2g7 and C57BL/6 mice were immunized with αDEC/GAG p41
along with αCD40. Two weeks after immunization IFNγ and IL-2 levels in
CD4 T cells were measured (Figure 5A, B and C). C57BL/6 mice made
strong IFNγ responses, while the responses in B6.H2g7 were significantly
lower (p value = 0.007). Interestingly, the IFNγ responses in NOD mice
were even lower than those of the B6.H2g7 (p value=0.025) (Figure 5D). The
diminished IFNγ responses of B6.H2g7 mice compared to the C57BL/6 mice
confirm studies by others, showing that the I-Ag7 is a defective MHC
molecule that leads to poor antigen presentation and dampened T cell
responses (139). The additional reduction in IFNγ responses in NOD CD4 T
cells points to non-I-Ag7 defects in the mounting of immunity against foreign
antigen in this strain. The defects are likely to lie in either the DCs or CD4 T
cells or both, since the targeted antigen delivery strategy uniquely involves
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these subsets. These results correlate with previous studies that have shown
defects in vitro in APCs and CD4 T cells from NOD (140, 141).

The NOD mouse has a recombinant MHC Class I locus consisting of H-2Kd
and H-2Db. To determine whether the CD8 T cell compartment in NOD is
also defective, we decided to immunize the mice with a recombinant
adenovirus carrying the GAG p41 protein (Adeno/GAG p41), which had
previously been reported to generate strong H-2Kd restricted IFNγ responses
in BALB/c mice (138). NOD mice and BALB/c controls were immunized
with a single intramuscular dose of the Adeno/GAG p41, and 2 weeks later
bulk splenocytes were restimulated in vitro with GAG p41 peptides and
assayed for intracellular IFNγ (Figure 6). The level of IFNγ made by the
CD8 T cells in NOD was comparable to BALB/c, suggesting that unlike the
CD4 T cell responses, the CD8 T cell responses against foreign antigen are
not deficient in NOD.

Having established detectable immune responses against the foreign GAG
p41 antigen in the NOD CD4 polyclonal repertoire, we wanted to know
whether targeting the antigen to DCs in the absence of adjuvant would lead
to antigen-specific tolerance in NOD T cells, as had been observed in the
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transgenic T cell models. A measure of such tolerance would be the
abrogation of cytokine production in response to immunogenic challenge
with antigen. We treated NOD mice with 5μg of αDEC/GAG p41, and
waited 7 days for tolerance to be established, in accordance with empirical
observations from the studies in transgenic models. The T cells were then
subjected to immunogenic challenge in the form of αDEC/GAG p41 in
conjunction with αCD40. 14 days after the challenge, bulk splenocytes were
isolated and restimulated in vitro with GAG p41 antigenic peptides and IFNγ
production was measured. NOD mice pretreated with the tolerizing regimen
of αDEC/GAG p41 showed no reduction in IFNγ levels in response to
challenge, when compared to control mice that had only received the
challenge (Figure 7).

The previous studies on T cell tolerance achieved by DC targeted antigen
delivery had been done in models that involved adoptive transfer of
transgenic T cells in wild-type mice (62, 106). The success in establishing
tolerance in these model T cells, had led us to believe that antigen-specific T
cells from autoreactive polyclonal repertoires could be tolerized in a similar
fashion. The failure to achieve antigen-specific tolerance in the NOD mice,
in the experiments detailed here, emphasized the challenges to achieving
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tolerance in disease-prone repertoires that have multiple defects in their DCs
and T cell compartments. These results also strongly brought into focus the
many important differences between polyclonal T cell repertoires and the
more simplistic transgenic models that had been studied before. Polyclonal T
cells have a wide range of affinities and specificities compared to the high –
affinity, single epitope specificity of transgenic T cells. Another major
difference in these experimental systems is that while adoptive transfer of
transgenic T cells involves following the fate of an unreplenishing
population of cells, wild type models have cells constantly emigrating from
the thymus and being turned over. A detailed discussion of these differences
and their potential impact on the establishment of tolerance is presented in
chapter 6. The results described above, brought us to the conclusion that any
attempt towards the challenge of tolerizing autoreactive disease-prone
repertoires, would have to be based on a thorough understanding of
tolerance in non-disease prone polyclonal repertoires.
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Figure 4. αDEC/GAG p41 generates IFNγ responses in B6.H2g7 mice.
B6.H2g7 mice were immunized i.p. with 5μg of either αDEC/GAG p41 (A)
or αDEC/OVA (B) in conjunction with 50μg αCD40. 2 weeks later, bulk
splenocytes were restimulated in vitro with either αCD28 alone, or GAG
p41 peptides with αCD28, and cells were stained for intracellular IFNγ.
Plots are gated on CD3 cells.
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Figure 5. αDEC/GAG p41 generates IFNγ responses in CD4 T cells in
NOD mice.
A) C57BL/6, B6.H2g7 and NOD mice (3 per group) were immunized i.p.
with αDEC/GAG p41 (5μg) in

αCD40 (50μg). 2 weeks later bulk

splenocytes were isolated and restimulated in vitro with GAG p41
peptides. After 6 hours, cells were fixed and stained for intracellular
IFNγ. Plots are gated on CD3 cells.
B) Percentage of IFNγ producing T cells in C57BL/6, B6.H2g7 and NOD
mice. Values represent means from 3 independent experiments as shown
in (A) with 3 mice per group. Error bars represent one standard error of
the mean. p-values were computed using Welch’s t-test (refer to Chapter
2).
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Figure 6. Adeno/GAG p41 generates IFNγ responses in CD8 T cells in
NOD.
NOD and BALB/c mice were vaccinated using one i.m. dose (1X107 PFU)
of Adeno/GAG p41. 14 days later, bulk splenocytes were isolated and
restimulated with GAG p41 peptide for 6 hrs, and intracellular IFNγ was
measured by flow cytometry. Plots are gated on CD3 cells.
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Figure 7. αDEC/GAG p41 does not tolerize αGAG p41-specific CD4
IFNγ responses in NOD mice.
NOD mice were injected i.p. with PBS or αDEC/GAG p41 (5μg ). 7 days
later, mice were immunized with αDEC/GAG p41 (5μg) and αCD40
(50μg). 14 days later bulk splenocytes were restimulated with GAG p41
peptide for 6 hrs, and intracellular IFNγ was measured by FACS. Plots are
gated on CD3 cells.
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Chapter 5
Results Part III
Tolerance in non-disease polyclonal repertoires

Our results from the studies in the previous chapters emphasized the need to
dissect the pathways and mechanisms of DC- mediated tolerance in
polyclonal T cell repertoires in non-disease models, as the basis for progress
towards achieving therapeutic tolerance in disease models. Towards this end,
we chose to study tolerance in wild type C57BL/6 mice, with chicken egg
ovalbumin (OVA) as the model antigen. Apart from being one of the most
characterized antigens, OVA has the rare advantage of possessing both welldefined MHC Class I and II epitopes. In choosing it for these studies, we
therefore hoped to gain insight into the similarities and differences between
the regulation of peripheral tolerance in the CD4 and CD8 T cell
compartments.

To deliver OVA protein to DCs in vivo, a hybrid antibody was produced as a
fusion protein with the full length OVA protein added to the carboxyl
terminus of the heavy chain of the cloned αDEC (referred to as
αDEC/OVA) antibody (Figure 8A). The DNA construct encoding this

50

hybrid antibody was transiently transfected into 293T cells, and the protein
was purified from the supernatant (Figure 8B).

We tested binding of hybrid αDEC antibody bearing the OVA protein, to the
DEC-205 receptor in an in vitro assay. We used CHO cells expressing the
DEC-205 receptor on their surface. αDEC/OVA was able to bind the DEC205 receptor even at concentrations as low as 0.1μg/ml (Figure 8C).

We immunized C57BL/6 mice with 5μg of αDEC/OVA in conjunction with
αCD40, to see whether we could detect measurable cytokine responses in
the polyclonal repertoire against the CD4 and CD8 T cell epitopes of OVA.
2 weeks later we isolated bulk splenocytes and restimulated in vitro with a
mix of αCD28 and peptide 75 (epitope 265-279) consisting of overlapping
Class I and II epitopes of OVA. αCD28, the TCR-independent T cell
costimulator (142) , was used to enhance T cell responses to facilitate
detection. In response to immunization with αDEC/OVA, the CD4 T cells
make low but detectable levels of IFNγ, and medium to high levels of IL-2
(Figure 9A and B). In the case of CD8 T cells, IFNγ responses are very
strong and IL-2 responses are undetectable. (Fig. 9C and data not shown).
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We also tried immunizations with DC maturation stimuli milder than
αCD40, specifically the TLR ligands polyIC and LPS, and Complete
Freund’s Adjuvant (CFA). These adjuvants had been shown to generate
robust transgenic T cell responses in conjunction with DC targeted antigen,
(62, 106) and our hope was that they would also prove effective in
generating polyclonal responses in our assays. However, no detectable
cytokine production was seen in response to any of these adjuvants (data not
shown) leading us to conclude that in order to visualize primary polyclonal
responses, a potent adjuvant such as αCD40 was necessary.

Having established detectable polyclonal CD4 and CD8 T cell cytokine
responses against immunogenic OVA, we wanted to examine whether
targeting the antigen to DCs in the absence of adjuvant would lead to
antigen-specific tolerance. A measure of such tolerance would be the
abrogation of cytokine production in response to subsequent immunogenic
challenge with antigen. We treated C57BL/6 mice with 5μg or 20μg of
αDEC/OVA and waited 10 days for tolerance to be established. The T cells
were then subjected to immunogenic challenge in the form of 5μg
αDEC/OVA in conjunction with αCD40. 14 days after the challenge, bulk
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splenocytes were isolated and restimulated in vitro with αCD28 and the
OVA peptide 75 bearing the Class I and II epitopes, and IFNγ and IL-2
production was measured. Neither CD4 nor CD8 T cells from mice
pretreated with the tolerizing regimen of αDEC/OVA, showed reduction in
the levels of IFNγ in response to challenge, when compared to IFNγ levels
from control mice that had only received the challenge (Figure 10A and data
not shown). Interestingly however, the CD4 T cells from mice pretreated
with the tolerizing regimen of αDEC/OVA, showed a reduction in IL-2
levels when compared to control mice that had only received the challenge.
(Figure 10B). The results were similar for mice treated with 5μg or 20μg of
αDEC/OVA preceeding immunization. Thus polyclonal wild type CD4 T
cells, when exposed to antigen in the absence of adjuvant are not deleted but
persist, and can respond to subsequent immunogenic challenge by producing
high levels of IFNγ, but can no longer make IL-2. This outcome is very
different from what we see in adoptively transferred transgenic T cells after
exposure to tolerizing antigen, where the T cells are either deleted, or persist
having lost all ability to make cytokines.

We decided to examine a panel of cytokines to see whether in addition to
IL-2, T cells exposed to tolerizing antigen lost or gained the ability to make
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other cytokines. We treated the mice with 5μg of αDEC/OVA in the absence
of adjuvant and 10 days later, immunized them with αDEC/OVA in
conjunction with αCD40. 14 days later, we isolated bulk splenocytes and
cultured them with peptide for 72 hours, after which the supernatants were
tested on a high-throughput LUMINEX assay for IFNγ, IL-10, IL-17, IL-4,
IL-12 and TNFα. Mice that had received the tolerizing regimen prior to
challenge, made low but detectable levels of IL-10 while mice that had
received only the challenge did not. All the other cytokines examined such
as TNFα were produced at comparable levels in both groups of mice (Figure
11 and data not shown). Thus in polyclonal T cells, the exposure to antigen
under tolerizing conditions alters the cells’ effector cytokine profile. The
cells continue to make IFNγ, but lose the ability to make IL-2, while gaining
the ability to make IL-10.

IL-10 is a anti-inflammatory cytokine induced under tolerogenic conditions
in certain subsets of suppressor T cells (129). Thus the presence of this
cytokine in mice exposed to the tolerizing regimen, suggested a skewing of
the Th1 polarized IFNγ response towards a pro-tolerance cytokine milieu.
We looked to see whether there was an increase in the numbers of
CD4+CD25+Foxp3+ cells, however we failed to see any difference in
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immunized mice compared to mice that had been exposed to αDEC/OVA
before immunization (data not shown).

To determine whether the alteration in effector cytokines upon tolerizing
antigen exposure, resulted in functional tolerance for the CD4 T cells, we
decided to examine antibody responses in these mice. B cells need CD4 T
cell help in order to make antibodies, and therefore if the CD4 T cells in our
mice are functionally tolerized, we would hypothesize that antibody
production in these mice would be diminished. C57BL/6 mice that are
immunized with either αDEC/OVA in conjunction with αCD40, or OVA
protein in alum followed by a boost 14 days later with NP-OVA, generate
OVA-specific and NP-specific antibodies, the peak titres of which are
between 14 and 21 days after the boost. Since αCD40 is a very potent
adjuvant, we worried that tolerized T cells exposed to it upon immunization,
might reverse tolerance. Alum on the other hand is an appropriately mild
adjuvant, and has been shown to produce detectable antibody titres, albeit
one order of magnitude lower than those produced by αCD40 (137). We
therefore chose to use both immunization protocols in mice pretreated with
tolerizing OVA, and expected to see a more dramatic reduction of antibody
titres in response to alum immunization as compared to αCD40
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immunization. We treated groups of 8 mice each, with either PBS, a single
dose of αDEC/OVA or three sequential doses of αDEC/OVA. The duration
between each dose of αDEC/OVA was 10 days. 10 days after the final dose,
we immunized the mice with either αDEC/OVA in conjunction with αCD40
or OVA in alum. 14 days later, the mice were boosted with NP-OVA, and
bled at day 14 post-boost. Anti-OVA and anti-NP antibody titres were then
measured using a capture ELISA with either OVA, or NP conjugated to
BSA respectively. We found that mice exposed to tolerizing antigen (single
or multiple doses) prior to immunization, showed between one and two log
diminished antibody titres, with both immunization regimens. The reduction
in antibody titres was greater in the case of the alum immunization, as
compared to the αCD40 immunization (Figure 12) Our results indicate that
treatment with αDEC/OVA in the absence of adjuvant leads to a special
form of anergy in polyclonal repertoires, where the CD4 T cells experience
not just an alteration in cytokine profiles, but also a loss in functional ability
to aid the B cells in mounting humoral responses.

We then decided to examine in vitro proliferative responses to antigenic
restimulation in CD4 and CD8 T cells from mice that had been exposed to
tolerizing antigen. We treated the mice with αDEC/OVA and 10 days later,
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immunized with αDEC/OVA in conjunction with αCD40. 14 days later,
bulk splenocytes were labeled with CFSE and pulsed with peptide with or
without αCD28 in vitro. 3 days later, cells were assayed for proliferation by
flow cytometry. We observed that both CD4 and CD8 cells that had been
exposed to tolerizing antigen prior to immunization, when pulsed with
αCD28, made stronger proliferative responses when compared to cells from
mice that had received only immunization. In contrast in the absence of
αCD28, tolerized mice showed a complete abrogation of proliferation in
both the CD4 and CD8 compartment (Figure 13 and 14). We therefore
conclude that tolerizing exposure to antigen in the polyclonal repertoire
leads to functional tolerance in both CD4 and CD8 T cells, one measure of
which is in vitro proliferation. αCD28, a potent stimulator of TCRindependent signaling in T cells, reverses proliferative arrest in the tolerized
mice. There are two explanations for this observation. Either, the αCD28 is
reversing anergy in the tolerized T cells, by pushing them into cycle, or it is
activating a hypo-responsive population of antigen-specific T cells, that had
hitherto been unresponsive to the antigen. The observation that cells from
tolerized mice that have seen antigen twice, i.e. during tolerization as well as
immunization, make stronger proliferative responses in the presence of
αCD28 than cells from immunized mice that have seen antigen only once,
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seems to suggest that the former explanation is more likely. Thus tolerized
CD4 and CD8 T cells, appear to be in a state of anergy that can be reversed
upon exposure to αCD28 mediated costimulation.

The results in this chapter show that polyclonal CD4 and CD8 T cells can be
tolerized by antigen delivered to DCs in the absence of inflammation. The
mechanisms and phenotype of this tolerance is very different from that seen
in the previously examined transgenic T cell models. Unlike transgenic T
cells which are either deleted or completely anergized, with no effector
responses in vivo and in vitro, polyclonal T cells persist after tolerance but
alter their cytokine profile. They continue to make IFNγ in response to
immunogenic challenge, but lose the ability to make IL-2, while gaining the
ability to make IL-10. The functional outcome of this tolerance is the loss of
CD4 T cell help to the antibody producing B cells. Thus antibody titres in
tolerized mice are significantly reduced. αCD40 as an adjuvant seems to
reverse tolerance to some extent, since in mice immunized with alum, there
is a more dramatic reduction in antibody titres compared to mice immunized
with αCD40. Tolerized CD4 and CD8 cells lose their ability to proliferate in
vitro in response to peptide restimulation. However restimulation in the
presence of αCD28 appears to reverse the proliferative block on the anergic
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T cells in vitro. These results suggest that this form of polyclonal tolerance
is very delicately held in balance and strong stimulation of the T cells under
conditions such αCD40 in vivo or αCD28 in vitro can reverse this tolerance
in both CD4 and CD8 subsets.

This susceptibility to reversal of T cell tolerance in wild type mice as
compared to transgenic models, could be explained by the nature of
polyclonal T cells. These cells range in affinities and specificities, with the
average affinity being lower than that of most high affinity, single specificity
transgenic T cells. In the case of transgenic T cells, strong signaling during
high affinity interactions with tolerizing antigen leads to deletion or
complete anergy. In contrast, in lower affinity polyclonal T cells, weaker
strength of signaling during interactions with tolerizing antigen may lead to
partial anergy that can be reversed under conditions of strong costimulation.
Thus polyclonal T cell tolerance has different mechanisms and differing
dynamics of establishment and reversal compared to transgenic models, and
the understanding of these differences is an important step towards
achieving tolerance in disease prone polyclonal repertoires and the therapy
of autoimmune disease.
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Figure 8. Design and characterization of the αDEC/OVA hybrid
antibody.
A) Schematic representation of the αDEC/OVA hybrid antibody.
B) SDS PAGE analysis of purified αDEC/OVA hybrid antibody followed
by Coomassie staining. αDEC was used as a loading control.
C) αDEC/OVA antibody was tested for in vitro binding to DEC-205
expressed on CHO cells (Titration range 5μg/ml - 0.01 μg/ml). Histogram
plots show mean fluorescence intensity of staining with secondary
αmouse IgG.
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Figure 9. αDEC/OVA generates detectable IFNγ and IL-2 responses in
CD4 and CD8 cells in C57BL/6 mice.
C57BL/6 mice were immunized i.p with αDEC/OVA (5μg) along with
αCD40 (50μg). Two weeks later bulk splenocytes were isolated and
restimulated in vitro with OVA peptide 75 containing Class I and II
epitopes. After 6 hours cells, were fixed and stained for intracellular IFNγ
and IL-2. Plots are gated on CD3 cells.
(A) IFNγ in CD4 cells. (B) IL-2 in CD4 cells. (C) IFNγ in CD8 cells.
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Figure 10. CD4 T cells from C57BL/6 mice treated with αDEC/OVA
prior to immunization, show reduced levels of IL-2 but not IFNγ,
following tolerization regimen.
C57BL/6 mice were injected with αDEC/OVA (5μg). 10 days later, mice
were immunized with αDEC/OVA (5μg) in conjunction with αCD40
(50μg). 14 days later, bulk splenocytes were isolated and restimulated in
vitro for 6 hrs, with αCD28 and the OVA peptide 75 bearing the Class I and
II epitopes. Intracellular IFNγ (A) and IL-2 (B) was measured by flow
cytometry. Plots are gated on CD3 cells.
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Figure 11. CD4 T cells from C57BL/6 mice treated with αDEC/OVA
prior to immunization, show increased levels of IL-10, following
tolerization regimen.
C57BL/6 mice were injected with PBS or αDEC/OVA (5μg). 10 days later,
mice were immunized with αDEC/OVA (5μg) in conjunction with αCD40
(50μg). 14 days later, bulk splenocytes were isolated and restimulated in
vitro for 72 hrs, with medium or the OVA peptide 75 bearing the Class I and
II epitopes. Supernatants were then assayed by LUMINEX for IL-10 and
TNFα. Values represent mean cytokine concentrations with 4 mice per
group. Error bars represent one standard error of the mean.

66

Figure 11

67

Figure 12. Single or multiple doses of αDEC/OVA prior to
immunization, abrogates antibody production in C57BL/6 mice.
Schematic representation of the protocols for tolerance induction, followed
by immunization with αDEC/OVA along with αCD40 (A), or OVA in alum
(D).
Groups of 8 mice each were treated with either PBS, a single dose of
αDEC/OVA or three sequential doses of αDEC/OVA at 10 day intervals. 10
days after the final dose, mice were immunized with either αDEC/OVA
along with αCD40, or OVA in alum. 14 days later, the mice were boosted
with NP11-OVA. Mice were bled 14 days post-boost. Symbols represent the
log of αOVA titres (B and E) and αNP titers (C and F) of individual mice
as measured by ELISA. Horizontal bars depict the mean of the log of the
antibody titers for each group.
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Figure 13. CD4 T cells from mice treated with αDEC/OVA prior to
immunization, do not proliferate in vitro in response to antigen.
Mice were treated with PBS or αDEC/OVA (5μg) and 10 days later,
immunized with αDEC/OVA (5μg) along with αCD40 (50μg). 14 days after
immunization, bulk splenocytes were labeled with CFSE and pulsed with
peptide with or without αCD28 in vitro. 3 days later, cells were assayed for
proliferation by flow cytometry. Plots are gated on CD3+CD4+ cells.
Identical gates have been applied to all samples.
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Figure 14. CD8 T cells from mice treated with αDEC/OVA prior to
immunization, do not proliferate in vitro in response to antigen.
Mice were treated with PBS or αDEC/OVA (5μg) and 10 days later,
immunized with αDEC/OVA (5μg) along with αCD40 (50μg). 14 days after
immunization, bulk splenocytes were labeled with CFSE and pulsed with
peptide with or without αCD28 in vitro. 3 days later, cells were assayed for
proliferation by flow cytometry. Plots are gated on CD3+CD8+ cells.
Identical gates have been applied to all samples.
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Chapter 6
Discussion
The intricate regulation of the immune system’s ability to distinguish self
from non-self is at the heart of what protects the animal from infection while
preserving it from self-destruction. The establishment and maintenance of
tolerance to self is a process that begins during fetal development and
continues through the life of the animal. The negative selection of
autoreactive T cells in the thymus, is a principal mechanism for the
establishment of tolerance, nevertheless not every autoreactive T cell is
deleted in the thymus. Some make it to the periphery, and in genetically predisposed individuals or special circumstances of inflammation and infection,
can lead to autoimmunity. The establishment and maintenance of peripheral
tolerance is therefore critical for the prevention of autoimmune disease.

An important fork in the divergent paths to immunity and tolerance in the
periphery is the presentation of antigen to the T cells by the DCs. The
context of the DCs during this presentation has been shown to be critical in
the decision between tolerance and immunity. We have devised a strategy to
deliver antigens specifically to DCs in situ, based on a genetically
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engineered hybrid antibody comprising the variable region specific for the
DEC-205 receptor on DCs, a constant region that was mutated to prevent
binding to Fc receptors, and antigenic protein or peptide fused to the
carboxyl terminus of the heavy chain. Using models of adoptive transfer of
transgenic T cells into wild type mice, it was shown that antigen presentation
by DCs in the steady state leads to tolerance, while presentation during
inflammation leads to immunity. The fate of tolerized transgenic T cells was
either deletion, or complete anergy. The anergy observed in these models
was complete paralysis of the T cells, where they ceased to proliferate or
make cytokines in response to subsequent challenge with immunizing
antigen both in vivo and in vitro.

These results in transgenic models suggested a promising novel approach to
prevention and therapy of autoimmune diseases. Our rationale was that
delivering autoantigens to DCs using the targeting strategy would lead to
tolerance of autoreactive T cells in the periphery, and the consequent
prevention of progression to autoimmune disease. To evaluate this strategy
of DC- targeted antigen therapy, we chose the experimental autoimmune
encephalomyelitis (EAE) mouse model for human multiple sclerosis (MS).
MS is an autoimmune condition affecting the central nervous system, with a
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relapsing-remitting or progressive course that often leads to paralysis or
even death. It is characterized by de-myelination of the neuronal sheath and
the presence of multiple scarred areas in the brain infiltrated by T cells and
macrophages. The EAE model of multiple sclerosis, is an acute model
induced by immunization with brain specific proteins and peptides (143,
144), including a peptide from myelin oligodendrocyte glycoprotein (pMOG
35-55) (145).

To deliver MOG peptide to DCs in vivo, hybrid antibodies were produced
with the MOG peptide fused to the carboxyl terminus of the cloned αDEC
antibody (αDEC/MOG) (Figure 1A). Our results demonstrate that treatment
of C57BL/6 mice with αDEC/MOG prior to immunization with MOG
peptide, protects them from developing disease (Figure 1B). Also treatment
with αDEC/MOG prevents accumulation of effector CD4 T cells in the
spinal cord (Figure 1C).

Our success in the prevention of EAE, led us to then investigate the
therapeutic potential of the DC based antigen delivery strategy in the NonObese Diabetic (NOD) mouse model. The NOD mouse is an important
model of autoimmune Type 1 diabetes because it shares many genetic,
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immunological and pathological similarities with the human disease (146150). The destruction of the insulin producing β cells in the pancreatic islets
by autoreactive CD4 and CD8 T cells leads to the disease. Diabetes onset
typically occurs at 12 to 14 weeks of age in female mice and slightly later in
male mice. Beginning as early as 3-4 weeks of age, both female and male
NOD mice demonstrate mononuclear infiltrates that surround the islet (periinsulitis). These infiltrates progress and invade the islets (insulitis) over the
subsequent few weeks. 60%-80% of females and 20- 30% males ultimately
progress to overt diabetes (146).

One of the most important loci in the genetic susceptibility to diabetes in
NOD, is H-2g7, the MHC locus. The MHC Class II I-Ag7 molecule encoded
by this locus has a low-affinity peptide binding groove, which has been
suggested to be involved in defective negative selection of autoreactive T
cells in the thymus (151, 152). Some of the major autoantigens implicated in
the pathogenesis of T1D are insulin, glutamic acid decarboxylase,
insulinoma-associated protein 2, IGRP and heat shock protein 60 (134).

To evaluate the therapeutic potential of the dendritic cell- targeted antigen
delivery strategy in the chronic spontaneous diabetes model, the 9-23
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peptide of the β chain of insulin was selected as the antigen of choice. This
peptide has both CD4 and CD8 immunodominant epitopes that have been
implicated in the disease (134). A hybrid antibody was produced with the
insulin peptide fused to the carboxyl terminus of the cloned αDEC antibody
(αDEC/INS) (Figure 2A). Chronic treatment of NOD mice with αDEC/INS
starting at age 5 weeks, failed to delay or prevent onset of diabetes (Figure
3A, B and C).

The failure of the autoantigen targeting strategy in NOD in contrast to EAE,
pointed to the complexities of the NOD disease model and the challenge of
tolerizing disease-prone polyclonal repertoires. The EAE model is an acute
induced model of autoimmunity, which means that the system is in a noninflamed steady state conducive to the induction of tolerance, until the time
when immunity- induced inflammation sets in. Also until induction of
disease, the MOG specific T cells are ignorant of their antigen, since it is
sequestered behind the blood-brain barrier. Thus when the MOG antigen is
presented for the first time, by steady state DCs to MOG-specific T cells in
the periphery, the outcome is tolerance.
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In striking contrast, the NOD model, which mimics progressive human
autoimmune disease, has a chronically inflamed immunological environment
from the time the mice are as young as 3-4 weeks old. Thus the DCs in this
model are most likely in a chronic state of activation, while the insulinspecific T cells encounter their circulating antigen via the DCs even before
treatment with αDEC/INS begins. Also in the EAE model the pathogenic T
cells that are induced by MOG peptide immunization, are of a single
specificity, and are addressed by the MOG peptide delivered through DC
targeting. In the NOD model of spontaneous autoimmunity however,
pathogenesis is caused by autoreactive T cells of varying islet specificities.
We had hoped that since the 9-23 epitope in insulin is immunodominant,
tolerizing autoreactive T cells against this epitope would suppress T cells
with other specificities as well (153). However, therapy in NOD using DC
based delivery of antigens, might require a combination of islet antigens in
order to be successful.

Our results made us realize that achievement of peripheral tolerance in NOD
is complicated by several factors, and insights into successful DC-based
therapeutic strategies would have to come from a thorough understanding of
DC regulation of peripheral T cell responses in NOD.
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To examine polyclonal T cell tolerance in NOD without the complicating
variables associated with autoantigens, we asked whether foreign antigenspecific peripheral tolerance could be achieved. The antigen that was chosen
for targeting to the DCs was the HIV GAG p41 protein which generated
detectable IFNγ responses in the I-Ag7-restricted CD4 compartment in
B6.H2g7 mice (Figure 4A). Consistent with in vitro studies by others (139),
the presence of the I-Ag7 molecule in the C57BL/6 background (B6.H2g7)
severely dampens T cell responses in comparison to those in wild type
C57BL/6 mice. However, the NOD mice appear to have additional
suppression of T cell responses compared to the B6.H2g7 mice (Figure 5).
These results indicate that not only is the MHC II in NOD mice defective,
but there are likely other defects in the DC and CD4 T cell compartments.
Others have reported defects in in vitro antigen presentation and
costimulation by NOD APCs. There have also been reports of enhanced
cytokine effector responses upon non-specific TCR stimulation in NOD as
compared to B6.H2g7 (141, 152). Our results in vivo however show
dampened IFNγ responses to immunizing antigen targeted to NOD DCs. In
the future it would be interesting to dissect whether the in vivo defect in
responsiveness that we see, lies in the DC or the CD4 compartment.
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To examine tolerance against the foreign GAG p41 antigen, NOD mice were
pretreated with αDEC/GAG p41 without adjuvant, prior to immunization
with αDEC/GAG p41 in conjunction with αCD40. This treatment with
αDEC/GAG p41 does not alter the ability of CD4 T cells to make IFNγ in
response to immunogenic challenge (Figure 7). Thus the effector cytokine
response in NOD was not altered by DC targeted antigen delivery, under the
conditions examined.

The failure to achieve tolerance in the disease- prone NOD repertoire,
brought into strong focus the need to study polyclonal tolerance in a nondisease prone model. Thus far all the studies on antigen targeting to DCs
have involved transgenic T cell models. In those simplistic systems tolerance
resulted in either deletion or complete anergy of the T cells, characterized by
a loss of proliferation and cytokine production. However, polyclonal models
have several complicating factors. Firstly, polyclonal T cells respond to
several different epitopes in an antigen, while transgenic T cells respond to a
single one. Thus tolerizing transgenic T cells is less challenging. Secondly,
for the same epitope specificity, there is a wide range of affinities amongst
poylconal cells, while transgenic T cells are of single specificity and high
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affinity. There is evidence that high affinity T cells upon interaction with
tolerizing antigen get deleted and thus tolerized, while lower affinity T cells
are not deleted but persist, and under certain conditions of inflammation
respond to immunogenic stimuli (154). Thirdly, experiments involving
transgenic T cells have always been carried out by adoptively transferring
these cells into a wild type mouse and then tracking their fate. This is
therefore a closed system which receives no input from the thymus, unlike
polyclonal wild type repertoires that are constantly being replenished from
the thymus (155). In a system of induced peripheral tolerance such as the
one studied here, the influx of naïve antigen specific T cells from the
thymus, although infrequent, could potentially lead to a reversal of tolerance
upon challenge. For all these reasons, establishment and maintenance of
tolerance in polyclonal models is considerably more difficult to achieve
when compared to tolerance in transgenic T cells.

We therefore decided examine in detail, the establishment and maintenance
of wild type polyclonal tolerance, to glean insights into the pathways of
immune regulation. C57BL/6 mice were studied for responses against the
CD4 and CD8 epitopes of OVA. Treatment with αDEC/OVA prior to
immunization with αDEC/OVA in conjunction with αCD40, leads to an
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alteration in the cytokine profile of the CD4 and CD8 T cells. Both CD4 and
CD8 T cells continue to make IFNγ while IL-2 levels are diminished in the
CD4 compartment (Figure 10). IL-2 is required to maintain proliferative
responses during clonal expansion in response to antigen challenge and for T
cell survival in vivo. In the absence of IL-2, effector CD4 and CD8 T cells
cannot survive long enough to become memory (156-158). Thus despite the
fact that the tolerized T cells continue to make IFNγ in the short-term (14
days), the lowered ability to make IL-2 probably impacts the longevity of
these cells, ultimately leading to death.

Since its discovery IL-2 was thought to be solely a pro-immune cytokine,
until that role was challenged by studies showing that mice deficient in IL-2
or its receptor components develop lymphoproliferative diseases and
autoimmunity (159, 160). Recent reports have explained this immunosuppressive role of IL-2, by demonstrating that it is crucial to the
development, survival and function of CD4+CD25+ T regulatory cells
(Tregs) (161). These results are now widely interpreted to be indicative that
IL-2 is crucial only for tolerance and not for immunity in vivo (161). Our
results however suggest that IL-2 might be required to maintain T cell
responses in vivo as functional tolerance correlates with the absence of this
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cytokine. There maybe a intricate balance between the effects of IL-2 on
Tregs versus effector T cells in vivo. Depending on whether IL-2 levels are
limiting, tolerance or immunity dominate. To test if the abrogation of T cell
responsiveness that we see in our system, is due to the loss of IL-2, we plan
to examine the consequences of supplying exogenous IL-2 in vivo. We
hypothesize that if the loss of IL-2 is responsible for the tolerance
established in vivo, then exogenous IL-2 would result in rescue of T cell
responsiveness.

To examine whether other cytokines produced by the T cells were altered
after tolerizing regimen of antigen, we tested a panel of different cytokines.
Tolerized T cells gained the ability to make low levels of IL-10, when
compared to immunized T cells. None of the other cytokines tested were
altered after exposure to the tolerizing regimen (Figure 11). IL-10 is a protolerance cytokine made by a subset of regulatory T cells under tolerogenic
conditions, that has been shown to suppress inflammatory responses in vivo
(129). We did not find an increase CD4+CD25+Foxp3+ regulatory cells in
mice that had been tolerized, indicating that the tolerance we see is possibly
mediated by an alteration in the cytokine mileu and the balance between
effector and suppressor cytokines such as IL-2 and IL-10.
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CD4 T cells that have been exposed to tolerizing antigen prior to
immunogenic challenge, lose their ability to provide help to B cells for
antigen-specific humoral responses. Mice receiving αDEC/OVA prior to
immunization had significantly diminished antibody titres compared to mice
that had only been immunized (Figure 12). Therefore targeting of antigen to
DCs in the steady state leads to polyclonal CD4 T cell tolerance, as well as
tolerance of the humoral responses against antigen.

The antibody titres were more diminished in the case of tolerized mice that
had been immunized with OVA in alum, compared to mice that had received
αDEC/OVA along with αCD40 (Figure 12). Thus the exposure of tolerized
polyclonal CD4 T cells to αCD40, which is a potent activator of DCs,
appears to induce some degree of reversal of tolerance in vivo. This result is
supported by a study on polyclonal CD8 T cells showing that high affinity T
cells are deleted in response to tolerizing antigen, while low affinity cells are
not deleted but persist, and can be reactivated upon potent costimulation
(154).
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CD4 and CD8 cells pretreated with the tolerizing regimen, failed to make
proliferative responses in vitro in response to peptide restimulation,
demonstrating that as a consequence of tolerance, T cells lose their ability to
cycle. This can be explained by the loss of IL-2, since it has been shown to
be indispensable for in vitro proliferation and differentiation of T cells (162).
Surprisingly, when CD4 and CD8 T cells were pulsed in vitro with peptide
in the presence of αCD28, the cells made stronger proliferative responses in
the tolerized mice compared to the immunized mice (Figure 13 and 14).
Thus both CD4 and CD8 T cells that are tolerized, fail to proliferate in vitro
upon restimulation with antigen. However, αCD28 can reverse the
abrogation in proliferation. There are two explanations for this observation.
Either, the αCD28 is reversing anergy in the tolerized T cells, by pushing
them into cycle, or it is activating a hypo-responsive population of antigenspecific T cells, that had hitherto been unresponsive to the antigen. The
observation that cells from tolerized mice that have seen antigen twice, i.e.
during tolerization as well as immunization, make stronger proliferative
responses in the presence of αCD28 than cells from immunized mice that
have seen antigen only once, seems to suggest that the former explanation is
more likely. Thus tolerized CD4 and CD8 T cells, appear to be in a state of
anergy that can be reversed upon exposure to αCD28 mediated
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costimulation. αCD28 is a potent costimulator of T cell activation that is
involved in stabilization of cytokine mRNA and long-lasting IL-2 secretion
and proliferation. Thus in the case of the tolerized CD4 and CD8 T cells,
αCD28 might be removing the proliferative block on the cells, by restoring
IL-2 secretion (142).

Concluding Remarks
Our results demonstrate that polyclonal T cell tolerance in a wild type
repertoire can be achieved by targeting of antigen to DCs in the steady state.
This tolerance seems to be a form of non-deletional, partial anergy. Unlike
anergic transgenic T cells, these cells do not completely lose their ability to
make cytokines. Instead they continue to make IFNγ while losing the ability
to make IL-2, and gaining the ability to make IL-10. This partial anergy can
be reversed with strong costimulatory stimuli, such as αCD40 in vivo and
αCD28 in vitro.

This susceptibility to reversal of T cell tolerance in wild type mice as
compared to transgenic models, could be explained by the nature of
polyclonal T cells. Polyclonal cells range in affinities and specificities, with
the average affinity being lower than that of most high affinity, single
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specificity transgenic T cells. In the case of transgenic T cells, strong
signaling during high affinity interactions with tolerizing antigen leads to
deletion or complete anergy. In contrast, in lower affinity polyclonal T cells,
weaker strength of signaling during interactions with tolerizing antigen may
lead to partial anergy that can be reversed under conditions of strong
costimulation.

Our results with polyclonal T cell tolerance in a non-disease prone
repertoire, provide an important understanding of the mechanisms and
regulation of peripheral tolerance in wild type mice. They offer critical
insight into why the establishment and maintenance of tolerance in models
with chronic inflammation and low affinity T cell repertoires such as NOD,
is a challenge.

This understanding is an important step towards the

successful design of antigen-specific DC based therapeutic strategies for
prevention and treatment of autoimmune disease.
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